338 related articles for article (PubMed ID: 25782658)
1. Pancreatic Enzyme Replacement Therapy and Coefficient of Fat Absorption in Children and Adolescents With Cystic Fibrosis.
Woestenenk JW; van der Ent CK; Houwen RH
J Pediatr Gastroenterol Nutr; 2015 Sep; 61(3):355-60. PubMed ID: 25782658
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
3. Meal patterns, dietary fat intake and pancreatic enzyme use in preadolescent children with cystic fibrosis.
Schall JI; Bentley T; Stallings VA
J Pediatr Gastroenterol Nutr; 2006 Nov; 43(5):651-9. PubMed ID: 17130744
[TBL] [Abstract][Full Text] [Related]
4. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
[TBL] [Abstract][Full Text] [Related]
5. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients.
Borowitz D; Stevens C; Brettman LR; Campion M; Chatfield B; Cipolli M;
J Cyst Fibros; 2011 Dec; 10(6):443-52. PubMed ID: 21831726
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption.
Calvo-Lerma J; Martínez-Barona S; Masip E; Fornés V; Ribes-Koninckx C
Rev Esp Enferm Dig; 2017 Oct; 109(10):684-689. PubMed ID: 28747058
[TBL] [Abstract][Full Text] [Related]
7. Nutrition and pancreatic enzyme intake in patients with cystic fibrosis with distal intestinal obstruction syndrome.
Declercq D; Van Biervliet S; Robberecht E
Nutr Clin Pract; 2015 Feb; 30(1):134-7. PubMed ID: 25288253
[TBL] [Abstract][Full Text] [Related]
8. Dependence of PERT endpoint on endogenous lipase activity.
Gao WY; Mulberg AE
Pancreas; 2014 Nov; 43(8):1232-8. PubMed ID: 25102439
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis.
Calvo-Lerma J; Boon M; Colombo C; de Koning B; Asseiceira I; Garriga M; Roca M; Claes I; Bulfamante A; Walet S; Pereira L; Ruperto M; Masip E; Asensio-Grau A; Giana A; Affourtit P; Heredia A; Vicente S; Andrés A; de Boeck K; Hulst J; Ribes-Koninckx C
J Cyst Fibros; 2021 Sep; 20(5):e33-e39. PubMed ID: 33279468
[TBL] [Abstract][Full Text] [Related]
10. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis.
Borowitz D; Goss CH; Limauro S; Konstan MW; Blake K; Casey S; Quittner AL; Murray FT
J Pediatr; 2006 Nov; 149(5):658-662. PubMed ID: 17095338
[TBL] [Abstract][Full Text] [Related]
11. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis.
Borowitz D; Stevens C; Brettman LR; Campion M; Wilschanski M; Thompson H;
J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):248-57. PubMed ID: 22266487
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of stool collections to measure efficacy of PERT in subjects with exocrine pancreatic insufficiency.
Caras S; Boyd D; Zipfel L; Sander-Struckmeier S
J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):634-40. PubMed ID: 21681115
[TBL] [Abstract][Full Text] [Related]
13. Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose.
Calvo-Lerma J; Roca M; Boon M; Colombo C; de Koning B; Fornés-Ferrer V; Masip E; Garriga M; Bulfamante A; Asensio-Grau A; Andrés A; de Boeck K; Hulst J; Ribes-Koninckx C
Pediatr Res; 2021 Jan; 89(1):205-210. PubMed ID: 32247283
[TBL] [Abstract][Full Text] [Related]
14. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
Kuhn RJ; Gelrud A; Munck A; Caras S
Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
[TBL] [Abstract][Full Text] [Related]
17. How macronutrients and pancreatic enzyme supplements dose variability affect fat, protein and starch absorption in children with cystic fibrosis.
Larriba R; Roca M; Masip E; Cañada-Martínez A; Ribes-Koninckx C; Calvo-Lerma J
Dig Liver Dis; 2023 Apr; 55(4):513-518. PubMed ID: 36435715
[TBL] [Abstract][Full Text] [Related]
18. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy.
Konstan MW; Stern RC; Trout JR; Sherman JM; Eigen H; Wagener JS; Duggan C; Wohl ME; Colin P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1365-71. PubMed ID: 15606399
[TBL] [Abstract][Full Text] [Related]
19. Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study.
Olsen MF; Kjøller-Svarre MS; Møller G; Katzenstein TL; Nielsen BU; Pressler T; Lewis JI; Mathiesen IH; Mølgaard C; Faurholt-Jepsen D
Nutrients; 2022 Mar; 14(7):. PubMed ID: 35405943
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
